View source for Ceretin 6 Preliminary Results

===Standard dosage testing Methods===

Subjects were 15 male and 15 female volunteers at the joint
[[PCAG]]/[[Cognivia]] testing facilities in [[Perplex City]]. All were graduates
over 18 years of age, and gave informed consent to the procedure which
was approved by the AUC oversight committee. Serious psychiatric or
medical illness, cognitive enhancer dependence in the last two years or
a history of substance abuse, resulted in exclusion. Mean age was 30.2
years (range 22-37 years). All were tested as genetically compatible
with Ceretin and all had used Ceretin in the past.

Subjects were tested on the WCAS (standardised) with additional
domain-specific modules (see additional resources for more details)
one month prior to drug administration. Comprehensive biometrics
and blood chemistry status were monitored with the APM module
(APM17, Academy Neuroscience Group, Perplex City).
Subjects underwent double-blind oral administration of a standard
dosage of Ceretin G6, Ceretin G5 or a placebo on hour 0. Subjects also
had an fTNI scan prior to administration in order to detect any anomalies.
During the testing, subjects continued to be monitored with the
APM module. Subjects were tested every three hours on the WCAS
(adaptive, abbreviated v3) while being monitored by magnetoencephalography
(MEG).